ShareValue scores for 2652.HK: Valuation 27, Quality 57, Growth 47, Health 38.

2652.HK
HKEX

CF PharmTech Inc

HK$17.22(+0.47%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

-9% to 9%
Valuation
27
Overvalued
Price vs Value
Quality
57
Moderate
Business Strength
Growth
47
Moderate
Revenue & Earnings
Health
38
Stressed
Financial Stability
Momentum
17
Bearish
Price Trend

Company Details

About

CF PharmTech, Inc. engages in research and development, production, and sale of respiratory drugs and other related medical products in China. It offers Shufeimin, an azelastine hydrochloride and fluticasone propionate nasal spray; ChangQi, a budesonide inhalation suspension solution; ChangShu, a salbutamol sulfate inhalation solution; and piezoelectric mesh nebulizer, electric nasal cleaner, BFS hypertonic and physiological seawater nasal cleansing fluid products under the ChangShu name. The company also develops products for the treatment of respiratory diseases, including allergic rhinitis, asthma, chronic obstructive pulmonary, respiratory infection, pulmonary fibrosis, pulmonary hypertension, and other respiratory diseases. In addition, it develops therapeutic products for respiratory and other diseases, such as inhalation spray and aerosol, dry powder inhaler, nebulization, nasal spray products, as well as liposomes. Further, the company provides CDMO/CMO technical services. CF PharmTech, Inc. was formerly known as Suzhou CF PharmTech Co., Ltd. CF PharmTech, Inc. was founded in 2007 and is based in Suzhou, China. Address: No. 16, Hucundang Road, Suzhou, China, 215143

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026